Document text
Principal Investigator: Peter Palese
Organization: ROCKEFELLER UNIVERSITY
Fiscal Year: 2024
Award: $862,508
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
Licensed influenza vaccines commonly elicit strain-specific immunity, failing to provide protection against
antigenically distinct strains with the capacity to cause pandemic outbreaks. Therefore, the development of a
universal influenza vaccine with the capacity to elicit lifelong protection against diverse influenza virus strains is
critically needed to prevent future influenza pandemics. Influenza hemagglutinin (HA) represents a key vaccine
target, as it is the major glycoprotein expressed on the surface of influenza virions and mediates viral entry and
fusion. HA comprises two distinct functional domains: (i) the globular head, which is highly variable due to
antigenic drift, and (ii) the stalk domain, which is structurally conserved among diverse influenza strains.
Influenza infection or vaccination commonly elicits immune responses against immunodominant, strain-specific
epitopes on the HA head. By contrast, immune responses against highly conserved epitopes are limited and
short-lived, despite conferring broad and heterologous protection. Refocusing the immune response towards
conserved, immunosubdominant HA epitopes, while avoiding eliciting strain-specific immunity, represents a
promising strategy for the development of a universal influenza vaccine that would confer broad protection
against diverse influenza strains. To achieve this, the proposed studies aim to develop and evaluate novel HA
immunogens, termed mosaic HAs (mHA), in which the immunodominant, strain-specific epitopes at the head
domain have been replaced from those of exotic HAs which humans are naïve, while immunosubdominant,
conserved epitopes have been retained. In previous studies, we have dissected the mechanisms by which
antibodies, through specific interactions of their Fc domains with activating Type I Fcγ receptors (FcγRs), such
as FcγRIIa on dendritic cells and with the Type II FcγR, CD23, on B cells modulate cellular and humoral immunity
against influenza, respectively. Given the immunomodulatory consequences of Fc-FcγR interactions, the
proposed studies will develop Fc-engineered mHA immunogens that will engage and activate specific FcγR
pathways on defined effector cell populations to elicit broad and long-lasting immunity against diverse influenza
strains. We anticipate that the proposed studies will lead to the design, selection, and pre-clinical evaluation of
innovative immunogens with the capacity to confer durable and heterologous protection against influenza. These
studies are expected to have important implications not only for our efforts towards the development of a
universal influenza vaccine, but also provide the framework for the design of vaccines with long-lasting and broad
protection against other viral pathogens, such as SARS-CoV-2.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><Antibodies><Antibody Response><Antigen-Antibody Complex><Antigenic Determinants><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Determinants><Blood Serum><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID-19 virus><COVID19 virus><Cell Maturation><Cell Mediated Immunology><Cell-Mediated Immunity><Cellular Immunity><Clinical Trials><CoV-2><CoV2><Complex><Dendritic Cells><Development><Disease Outbreaks><Effector Cell><Engineering><Epitopes><Evaluation><Fc domain><Flu vaccination><Foundations><Funding><Future><Germinal Center><Glycoproteins><Grippe><Head><Hemagglutinin><Human><Humoral Immunities><IgG><Immune><Immune Complex><Immune response><Immunes><Immunity><Immunoglobulin G><Immunological response><Immunomodulation><Influenza><Influenza HA><Influenza Hemagglutinin><Influenza Vaccines><Influenza immunization><Influenza vaccination><Intramuscular><Licensing><Mediating><Messenger RNA><Mice><Mice Mammals><Modern Man><Mouse Strains><Mucosal Immunity><Murine><Mus><Outbreaks><Pathway interactions><Population><Prophylactic vaccination against influenza><Receptor Protein><Recombinant Proteins><Route><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Series><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Structure of germinal center of lymph node><Surface><T cell response><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Testing><Transgenic Mice><Vaccination><Vaccine Design><Vaccine Production><Vaccines><Veiled Cells><Viral><Virion><Virus Particle><Wuhan coronavirus><access to vaccination><access to vaccines><anti-flu><anti-influenza><antibody-based immunity><antiflu><coronavirus disease 2019 virus><coronavirus disease-19 virus><design><designing><developmental><engineered immune system><flu HA><flu hemagglutinin><flu immunisation><flu infection><flu serotype><flu strain><flu subtype><flu vaccine><flu viral strain><flu virus infection><flu virus pandemic><flu virus strain><flu virus vaccine><hCoV19><host response><immune engineering><immune modulation><immune regulation><immune system response><immunization strategy><immunoengineering><immunogen><immunogenicity><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><in vivo><infected with flu><infected with flu virus><infected with influenza><infected with influenza virus><influenza infection><influenza serotype><influenza strain><influenza subtype><influenza viral HA><influenza viral hemagglutinin><influenza viral strain><influenza virus HA><influenza virus hemagglutinin><influenza virus infection><influenza virus pandemic><influenza virus strain><influenza virus vaccination><influenza virus vaccine><innovate><innovation><innovative><mRNA><mosaic><nCoV2><new vaccines><next generation vaccines><novel><novel vaccines><pan influenza vaccine><pan influenza viral vaccine><pan influenza virus vaccine><pandemic><pandemic disease><pandemic flu><pandemic influenza><pandemic strain of influenza><pathogenic virus><pathway><pre-clinical evaluation><preclinical evaluation><prevent><preventing><produce vaccines><protective efficacy><receptor><response><thymus derived lymphocyte><universal flu vaccine><universal influenza vaccine><universal influenza virus vaccine><universal vaccine><universal vaccine against flu><universal vaccine against influenza><vaccination access><vaccination against influenza><vaccination availability><vaccination strategy><vaccine access><vaccine against flu><vaccine against influenza><vaccine availability><vaccine formulation><vaccine platform><viral pathogen><virus pathogen>